---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-027034"
form_type: "8-K"
ticker: "BACK"
cik: "0001729944"
company_name: "IMAC Holdings, Inc."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:02:24.991745+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ignite Proteomics (BACK) enters $420K biomarker study with Inova for GI cancers

## Summary
- Subsidiary Ignite Proteomics will analyze up to 600 tumor samples using RPPA technology.
- Maximum contract value $420,000; $175,000 payable upon execution.
- Data on 32+ protein biomarkers including HER2, RET, MHC-II, EGFR, TROP2, AKT, ERK.
- Results provided to Inova's Molecular Tumor Board to guide late-stage gastrointestinal cancer therapy.
- Agreement expected to contribute meaningfully to Ignite's 2025 revenue.

## SEC filing metadata
- accession: 0001641172-25-027034
- form_type: 8-K
- ticker: BACK
- cik: 0001729944
- company_name: IMAC Holdings, Inc.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729944/000164117225027034/0001641172-25-027034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729944/000164117225027034/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-027034
- JSON: https://secwatch.observer/filing/0001641172-25-027034.json
- Plain text: https://secwatch.observer/filing/0001641172-25-027034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.